Day 3 Saturday, March 23, 2024

E : English
BS : Breakfast Seminar LS : Luncheon Seminar

7:30 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00

Tokyo International Forum

Hall Building

Room 1 — 4F Hall C
- 9:05~11:05 Symposium 7 — Up-to-Date on GVHD — Yoshinobu Maeda, Takanori Teshima — P.12
- 11:25~12:15 LS14 (E) — Ruxolitinib for chronic GVHD — Speaker: Robert Zeiser — Chair: Takanori Teshima — (Novartis Pharma K.K.)
- 12:30~13:00 Awards ceremony
- 13:00~13:20 JSTCT Prize Commemorative Lecture — P.12
- 13:25~14:25 Special Lecture — Speaker: Natsuko Katayama — Chair: Shuichi Taniguchi — P.12
- 14:30~15:15 Plenary Session — Yoshiki Akatsuka, Masayuki Hino — P.13
- 15:20~17:05 Symposium 8 — Symposium Commemorating the 50th Anniversary of Allo-HSCT — Makoto Murata, Toshihiro Miyamoto — P.14
- Closing Remarks

Room 2 — 7F Hall B7 (1)
- 9:05~11:05 Nursing Symposium — Supporting the "Life" of the Elderly: Lights and Shadows of Life — Mitsuko Mori, Rie Tsuruta — P.15
- 11:25~12:15 LS15 — Rehabilitation practices and challenges for elderly patients - Focusing on blood cancer — Speaker: Tetsuya Tsuji — Chair: Reiko Yamahana — (Chugai Pharmaceutical Co., Ltd.)
- 13:40~14:20 Nursing Oral Session 2 — Transplant Nursing — Tomoko Yashima, Ikue Okuda — P.92
- 14:25~15:25 Team Approach 2 — Collaboration between HCTC and Nurses — Kanayo Takahashi, Chieko Indo — P.15
- 15:30~16:30 Brush up on LTFU Nurse — Inter-Hospital Collaboration for LTFU — Aya Miyake — P.16

Room 3 — 7F Hall B7 (2)
- 8:00~8:50 BS1 — Acute leukemia cellular heterogeneity and treatment resistance — Speaker: Koichi Takahashi — Chair: Takahiro Maeda — (Pfizer Japan Inc.)
- 9:05~10:45 Symposium 9 — Expanding HSCT in Japan: Counterattack from Regional Areas — Toshihiro Miyamoto, Katsuto Takenaka — P.16
- 11:25~12:15 LS16 — MRD in stem cell transplant — Speaker: Shin Mineishi — Chair: Yoshikane Kikushige — (Astellas Pharma Inc.)
- 13:20~14:50 Symposium 10 — Demands on transplantion for Advanced and High-Risk diseases in the Era of Molecular Targeted TherapiesTargeted Therapies — Ken-Ichi Matsuoka, Yoshikane Kikushige — P.17
- 15:00~16:30 Symposium 11 — Life-long Follow-up of HSCT Recipients — Kimikazu Matsumoto, Yuki Asano-Mori — P.17

Room 4 — 5F Hall B5
- 8:55~9:25 EL5 — Speaker: Fumihiko Ishikawa — Chair: Yasushi Miyazaki — P.18
- 9:30~10:00 EL6 — Speaker: Takahiro Maeda — Chair: Akiyoshi Takami — P.18
- 10:05~10:35 EL7 — Speaker: Nobuhiro Tsukada — Chair: Kazutaka Sunami — P.18
- 10:40~11:10 EL8 — Speaker: Keiji Okinaka — Chair: Hiroyuki Fujita — P.18
- 11:25~12:15 LS17 (E) — How to Maximize the Benefit of Immune-based Therapies in RRMM — Speakers: Tadao Ishida, Salomon Manier — Chair: Toshihiro Miyamoto — (Bristol-Myers Squibb K.K.)
- 12:30~13:30 Nursing Group Meeting
- 14:40~16:40 Public Forum

Room 5 — 7F Hall D7
- 8:00~8:50 BS2 — Up to Date on Acute Leukemia – Pitfall of Diagnosis - — Speaker: Toshihiro Miyamoto — Chair: Kinuko Mitani — (Incyte Biosciences Japan)
- 9:05~10:05 Symposium12 — Oral Care for "Life": The Importance of Interdisciplinary Collaboration — Yoshihiko Soga, Mieko Yoshimura — P.19
- 10:40~11:10 EL9 — Speaker: Takaaki Konuma — Chair: Tatsuo Ichinohe — P.19
- 11:25~12:15 LS18 (E) — The importance of anti CD38 therapy in upfront treatment for Multiple Myeloma. — Speaker: Krina K. Patel — Chair: Naoki Hosen — (Janssen Pharmaceutical K.K.)
- 13:35~14:05 EL10 — Speaker: Shigeo Fuji — Chair: Yuichiro Nawa — P.19
- 14:10~14:40 EL11 — Speaker: Yoshinobu Kanda — Chair: Rika Sakai — P.20
- 14:45~15:15 EL12 — Speaker: Go Yamamoto — Chair: Takashi Ikeda — P.20

Room 6 — 5F Hall D5
- 8:00~8:50 BS3 — Role of hematopoietic stem cell transplantation and immunosuppressive therapy in patients with aplastic anemia — Speaker: Shinichi Kako — Chair: Naoshi Obara — (Novartis Pharma K.K.)
- 9:05~11:05 Symposium13 — Industry-Academia-Government Collaboration Program for Cell Therapy — Koji Kato, Yoshiko Atsuta — P.20
- 11:25~12:15 LS19 (E) — CAR T treatment up to date - efficacy and safety management - — Speaker: Olalekan O. Oluwole — Chair: Koji Kato — (Gilead Sciences)
- 13:30~15:00 Workshop 5 — Machine Learning/ Artificial Intelligence — Rui Yamaguchi, Junya Kanda — P.21
- 15:30~16:30 HCTC Recertification Seminar

Room 7 — 1F Hall D1
- 8:00~8:50 BS4 — Current Issues and challenges of allo PBSCT - Prospect for allo PBSCH by G-LASTA~ — Speaker: Koji Nagafuji — Chair: Masayuki Hino — (Kyowa Kirin Co., Ltd.)
- 9:10~9:58 Oral Session 32 — Post-transplant relapse — Masuho Saburi — P.60
- 10:10~11:10 Oral Session 33 — Treatment for relapse /maintenance therapy — Hiroki Hosoi — P.61
- 11:25~12:15 LS20 — Considering Multiple Myeloma Treatment from the Perspective of Physicians and Patients — Speakers: Ryosuke Ogawa, Yoichi Imai — Chairs: Yoichi Imai, Ryosuke Ogawa — (Takeda Pharmaceutical Company Limited)
- 13:45~15:09 Oral Session 34 — Infections: Others — Shun-Ichi Kimura — P.62
- 15:20~16:20 National Survey News

Glass Building

Room 8 — 4F G402
- 8:00~8:50 BS5 — Hematopoietic stem cell transplantation for Inborn errors of metabolism — Speakers: Hiromasa Yabe, Chika Nitani — Chair: Hiromasa Yabe — (Clinigen K.K.)
- 9:00~10:12 Oral Session 35 — Late complications: Others 1 — Haruko Tashiro — P.63
- 10:15~11:15 Oral Session 36 — Unrelated donor bank /donor-related — Shohei Yamamoto — P.64
- 11:25~12:15 LS21 — Current treatment strategies for relapsed and refractory multiple myeloma — Speaker: Shuji Ozaki — Chair: Shinsuke Iida — (ONO PHARMACEUTICAL CO.,LTD.)
- 13:45~14:57 Oral Session 37 — CAR-T 4 — Hidehiro Itonaga — P.65
- 15:10~16:22 (E) Oral Session 38 — CAR-T 5 — Shigeo Fuji — P.66

Room 9 — 4F G409
- 8:00~8:50 BS6 — Current issues and future prospects of LTFU — Speakers: Ayako Mori, Hisayo Doi — Chair: Yoshihiro Inamoto — (Meiji Seika Pharma Co.,Ltd.)
- 9:00~9:48 Oral Session 39 — Transplant outcomes: AA — Chiharu Sugimori — P.67
- 10:10~11:10 Oral Session 40 — Immunotherapy and cell therapy — Yoshikiyo Ito — P.68
- 11:25~12:15 LS22 — High-dose chemotherapy with auto-SCT for pediatric malignant solid tumor — Speakers: Kimikazu Matsumoto, Eiko Shibata — Chair: Junichi Hara — (Sumitomo Pharma Co., Ltd.)
- 13:45~14:57 Oral Session 41 — SOS 1 — Koji Kawamura — P.69
- 15:10~15:58 Oral Session 42 — SOS 2 — Kota Yoshifuji — P.70

Room 10 — 5F G502
- 8:00~8:50 BS7 — Precision medicine of Polycythemia Vera based on the latest evidence — Speaker: Yuka Sugimoto — Chair: Katsuto Takenaka — (PharmaEssentia Japan)
- 9:10~9:46 Oral Session 43 — Histocompatibility antigen — Takashi Toya — P.71
- 9:55~11:07 Oral Session 44 — Rehabilitation 1 — Daisuke Kiguchi — P.72
- 11:25~12:15 LS23 — HSCT or Immunosuppressive therapy? ~Up to Date in the Treatment of Aplastic Anemia — Speakers: Shinichi Kako, Atsushi Narita — Chair: Mineo Kurokawa — (Pfizer Japan Inc.)
- 13:45~14:33 Oral Session 45 — Stem cell mobilization and harvesting 1 — Yasushi Onishi — P.73
- 14:45~15:45 Oral Session 46 — Stem cell mobilization and harvesting 2 — Masaki Ri — P.74

Room 11 — 5F G510
- 9:00~10:12 Oral Session 47 — Conditioning 2 — Hisashi Yamamoto — P.75
- 10:15~11:15 Oral Session 48 — Conditioning 3 — Tetsuya Nishida — P.76
- 11:25~12:15 LS24 — Better Hematopoietic cell transplantation medicine — Speaker: Tomoyasu Jo — Chair: Yoshiko Atsuta — (Otsuka Pharmaceutical Co., Ltd.)
- 13:45~14:45 Oral Session 49 — aGVHD 1 — Naoki Shingai — P.77
- 15:05~16:17 Oral Session 50 — aGVHD 2 — Daigo Hashimoto — P.78

Room 12 — 6F G602
- 9:00~10:00 Oral Session 51 — Transplant outcomes: MM — Senji Kasahara — P.79
- 10:10~11:10 Oral Session 52 — Late complications: Others 2 — Taku Kikuchi — P.80
- 11:25~12:15 LS25 — Treatment and Prevention of COVID-19 Focusing on patients with Oncology and Hematologic Malignancy — Speaker: Keiji Okinaka — Chair: Hirohito Yamazaki — (Astrazeneca K.K)
- 13:45~14:45 Oral Session 53 — Transplant outcomes: ML/ATL 1 — Koji Kato — P.81
- 14:55~15:55 Oral Session 54 — Transplant outcomes: ML/ATL 2 — Koji Izutsu — P.82

Room 13 — 6F G610
- 9:40~11:04 Oral Session 55 — Transplant outcomes: ALL — Maki Hagihara — P.83
- 11:25~12:15 LS26 — Management of VOD/SOS in real-world clinical practice — Speaker: Yuho Najima — Chair: Takayuki Ikezoe — (Nippon Shinyaku Co., Ltd.)
- 13:45~14:33 Oral Session 56 — Rehabilitation 2 — Takahiro Takekiyo — P.85
- 14:45~15:57 Oral Session 57 — Rehabilitation 3 — Kazushi Nakamura — P.86

Room 14 — 7F G701
- 8:00~8:50 BS8 — Up-to-date on the treatment of pediatric/AYA patients with B-ALL — Speaker: Katsuyoshi Koh — Chair: Keizo Horibe — (Pfizer Japan Inc.)
- 9:10~9:58 Oral Session 58 — Infections: HHV6 — Keisuke Kataoka — P.87
- 10:10~11:10 Oral Session 59 — Infections: Viral 1 — Ayumu Ito — P.88
- 11:25~12:15 LS27 — The transition of treatment for advanced-stage Mantle Cell Lymphoma — Speaker: Daisuke Kaji — Chair: Takuro Kuriyama — (SymBio Pharmaceuticals Limited)
- 13:45~14:33 Oral Session 60 — Infections: Viral 2 — Masahiro Ashizawa — P.89
- 14:45~15:45 Oral Session 61 — cGVHD 3 — Junichi Sugita — P.90

Hall E

Poster — B2F
- 9:00~16:00 Poster viewing
- 16:00~16:30 Poster removal

Exhibition — B2F
- 9:00~16:30 Exhibition